Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, July 11, 2013 LONDON, July 11, 2013 /PRNewswire/ -- On Wednesday, July 10, 2013, shares in biotechnology companies ended mostly higher even as the broader market ended on a mixed note. The major movers in the industry included Amgen Inc. (NASDAQ: AMGN), PDL BioPharma Inc. (NASDAQ: PDLI), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). All these companies are tracked by AAAResearchReports.com. Free technical research reports on AMGN, PDLI, QCOR, and BCRX can be accessed by signing up at: http://www.aaaresearchreports.com/register/ Shares in Amgen Inc. rose sharply on Wednesday, extending their gains for the week. The company's shares oscillated between $98.02 and $102.33 before finishing the day 3.79% higher at $102.26. A total of 4.18 million shares were traded which is above the daily average volume of 3.55 million. The company's shares have gained 4.53% so far this week, compared to a gain of 1.27% in the S&P 500. However, in the last three months, the stock has fallen by 5.72%. Download free report on AMGN upon registration at: http://www.AAAResearchReports.com/AMGN071113.pdf PDL BioPharma Inc.'s stock edged higher on Wednesday, extending its gains for the week. The company's shares oscillated between $8.06 and $8.15 before closing the session 1.24% higher at $8.15. A total of 1.71 million shares were traded which is below the daily average volume of 1.95 million. PDL BioPharma's shares have gained 3.16% so far this week, and 7.24% in the past three months, thus outperforming the S&P 500. PDLI technical report can be accessed for free by signing up at: http://www.AAAResearchReports.com/PDLI071113.pdf Shares in Questcor Pharmaceuticals Inc. edged lower on Wednesday, reversing some of their gains for the week. The company's shares ended the day 1.36% lower at $47.20 after oscillating between $47.04 and $48.57. A total of 1.87 million shares were traded which is below the daily average volume of 2.02 million. Despite Wednesday's pullback, the company's shares have gained 1.20% in the last three days and 63.95% in the last three months. A free report on QCOR can be accessed by registering at: http://www.AAAResearchReports.com/QCOR071113.pdf BioCryst Pharmaceuticals Inc.'s stock ended slightly higher on Wednesday, finishing at $1.63, up 0.62% from its previous closing price. The company's shares oscillated between $1.61 and $1.65. A total of 330,626 shares were traded which is less than its daily average volume of 818,150. The company's shares have fallen by 6.32% in the last three months. Register with AAA Research Reports and download research on BCRX for free at: http://www.AAAResearchReports.com/BCRX071113.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE AAA Research Reports Contact: AAAresearchreports.com, Phone #: +1(646)396-9126
Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
Press spacebar to pause and continue. Press esc to stop.